404 related articles for article (PubMed ID: 34718347)
1. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer.
Yu C; Luo D; Yu J; Zhang M; Zheng X; Xu G; Wang J; Wang H; Xu Y; Jiang K; Xu J; Ma X; Jing J; Shi H
Oncogene; 2022 Jan; 41(2):191-203. PubMed ID: 34718347
[TBL] [Abstract][Full Text] [Related]
2. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
3. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
5. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on
Kim KO; Park WJ; Jung Y; Lee WS
J Chemother; 2020 Dec; 32(8):437-444. PubMed ID: 33052075
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
9. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
10. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.
Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S
Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591
[No Abstract] [Full Text] [Related]
13. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
[TBL] [Abstract][Full Text] [Related]
14. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A
Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
16. RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.
Šuštić T; Bosdriesz E; van Wageningen S; Wessels LFA; Bernards R
Transl Oncol; 2020 Feb; 13(2):201-211. PubMed ID: 31865182
[TBL] [Abstract][Full Text] [Related]
17. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy.
Turner E; Chen L; Foulke JG; Gu Z; Tian F
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358868
[No Abstract] [Full Text] [Related]
20. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
